LifeArc and Sarcoma UK fund research to guide treatment decisions in rare cancer
LifeArc announces strategic partnership with PrecisionLife as part of its Motor Neuron Disease Translational Challenge
Filter by:
  • All
  • Articles & blogs
  • Ventures Funding
    • News Releases 5 September 2007

    Intellect Neurosciences and MRCT to humanize antibodies for AD

    MRCT will use its proprietary technology and advanced know-how to humanize Intellect’s beta-amyloid specific, monoclonal antibodies for the treatment of Alzheimer’s disease. The antibodies are intended as a form of passive immunization to promote clearance from the brain of the endogenous soluble Alzheimer’s toxin, beta-amyloid, where it accumulates and causes devastating damage to victims of the disease. Humanization is an essential step in making antibodies safe for use in humans.
    News Releases 25 July 2007

    Organon and MRC Technology sign antibody development agreement

    The collaborative agreement will cover development of a humanised antibody for the treatment of certain forms of cancer. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary CDR grafting technology to generate a humanised clinical candidate from a murine antibody discovered at Organon’s Research Center in Cambridge, MA,.
    News Releases 28 February 2007

    MRCT to humanize antibody to treat SLE

    SLE is a very important disease area, affecting over 1.5 Million people in the USA without any effective therapies. MRCT will use its proprietary humanization technology to generate the humanized clinical candidate from Ginkgo Biomedical Research Institute's mouse antibody.
    News Releases 2 October 2006

    MRCT to humanize antibody to treat AD

    MRC Technologyand BioArctic Neuroscience have signed an collaborative research agreement to humanise a mouse antibody under development with BioArctic for the treatment of Alzheimer’s disease. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary humanisation technology to generate the humanised clinical candidate.
    News Releases 12 July 2006

    Domantis wins award

    Domantis, a spin-out company from the MRC, is the first to win the UK Innovation in Drug…
    News Releases 15 June 2006

    MRCT recommended by select committee

    House of Commons Science and Technology select committee report recommends MRCT as model for commercialising research.
    News Releases 6 June 2006

    TYSABRI gains market approval

    Biogen Idec and Elan Corporation yesterday announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI® (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses.
    News Releases 6 March 2006

    MRCT and Chinese National Centre collaborate on malaria

    MRCT's Drug Discovery Group has developed a drug screening assay for a potential Malaria drug target called PfSub-1, a subtilisin-like protease, and successfully identified a small number of ‘hit’ compounds from its own in house chemical library. The collaboration with NCDS will allow the target to be screened against a much larger compound library. Apart from synthetic chemicals, the NCDS library also contains a large collection of compounds isolated from natural products including traditional Chinese herbs.
    News Releases 5 December 2005

    Therapeutic Antibody Group starts

    The Therapeutic Antibody Group (TAG) will comprise former AERES scientists. As part of MRCT’s evolving strategy of adding significant value to key MRC intellectual property assets, TAG will collaborate with MRC scientists to translate innovative drug targets into potent and selective therapeutic antibody candidates which can then be partnered with industry for progression into pre-clinical and clinical studies.